BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, has entered a collaboration with Janssen Biotech Inc., a Johnson & Johnson company.   The goal of this strategic collaboration is to combine the drug discovery, clinical development and data science expertise from Johnson & Johnson with BigHat’s Milliner platform, a suite of machine learning technologies integrated with a high-speed wet lab, t...